HROW at a glance
HARROW, INC. (HROW, SEC CIK 1360214) filed its latest 10-K annual report on March 2, 2026, a 10-Q quarterly report on November 9, 2026, an 8-K current report on November 16, 2026 and Form 4 insider filings as recently as August 17, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), HARROW, INC. (HROW) reported revenue of $272.3 million (up 36.4% from FY2024) and a net loss of $5.1 million. Diluted EPS was -$0.14.
- As of September 30, 2026, 27 institutional investment managers tracked by SignalX reported holding HARROW, INC. (HROW) shares worth $265.4 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Shojaei Amir on August 14, 2026 of 11,250 shares at $40.00 per share.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $272.3M
- +36.4% vs prior year
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 27 funds
- $265.4M · +0 vs prior quarter
- Latest 8-K
- Nov 16, 2026
- Item 7.01
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 31, 2025
Business Overview
- Core business: U.S. ophthalmic disease management with FDA-approved branded pharmaceuticals and ophthalmology-focused pharmaceutical compounding
- New product emphasis: Commercial launches planned for BYOOVIZ and BYQLOVI in mid-2026; OPUVIZ expected mid-2027; MELT-300 sedation tablet with FDA NDA filing expected H1 2027
- Strategic shift: Full acquisition of Melt Pharmaceuticals in Nov 2025, integrating MELT-300 non-IV sedation program into Harrow's pipeline and consolidating R&D
- Quantitative highlight: Ownership increased MELT to 100% via $4.3M upfront and contingent milestone payments; ImprimisRx serves 10,000+ U.S. eyecare prescribers
- Noteworthy fact: MELT-300 poised as first FDA-approved non-opioid, sublingual sedation therapy targeting broad procedural sedation beyond ophthalmology
Risk Factors
- Legal risk: Ocular Science lawsuit with $11.25M judgment after punitive damages reduction and pending appeal filed October 9, 2025
- Macroeconomic risk: Sole U.S. revenue and asset concentration with 90% accounts receivable from three customers as of December 31, 2025
- Operational risk: Contract manufacturing commitments of $10.7M for 2026 with minimum annual order requirements
- Competitive risk: ImprimisRx segment faces revenue decline from $83.5M in 2024 to $76.5M in 2025 amid competitive pressures
- Financial risk: Customer concentration with two customers accounting for over 10% of Branded revenues in 2024 and 2025 affecting revenue stability
Management Discussion & Analysis
- Revenue $272.3M up 36% YoY from $199.6M; IHEEZO sales $81.3M (+65% YoY), VEVYE sales $88.7M (+216% YoY), Other branded sales down $12.5M
- Gross margin branded 81.0% vs 81.3% prior year, ImprimisRx margin 59.9% down from 67.0%, net loss narrowed to $5.1M from $17.5M
- Best performing segment: Branded products revenue $195.8M up $79.6M; Worst: ImprimisRx revenue $76.5M down $7.0M
- Operating cash flow positive $43.9M vs negative $22.2M prior year; Capex and acquisition spend $5.5M; Debt refinancing with $242.7M 8.625% notes issued, prior debt paid off
- Management expanding commercial sales teams in 2026; pipeline growth supported by Melt acquisition, new product launches BYOOVIZ and BYQLOVI mid-2026; key risks include regulatory and reimbursement challenges
AI summary of the HROW 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Management Discussion & Analysis
- Q3 revenue $99.297M, up $27.659M YoY from $71.638M
- Best performer VEVYE, revenue $39.699M, up $17.073M YoY
- Worst performer compounding, revenue $15.835M, down $4.221M YoY
- Branded gross margin 79.3% vs 81.6% YoY, compounding margin 55.2% vs 59.0%
- Cash $75.336M at September 30, operating cash flow nine-month use $27.363M; $48.915M financing inflow from 2030 Notes
- TYRVAYA expected to contribute over $30M revenue in 2027, with approximately $20M annual operating expenses; licensor discussions remain unresolved
Risk Factors
- New risk: TYRVAYA acquisition triggered potential VEVYE license conflict, requiring divestiture or rights termination
- Financial risk: Up to $70,000,000 in TYRVAYA contingent milestone payments may remain payable
- Regulatory risk: Proposed CMS GLOBE and GUARD models could increase ophthalmic-product rebates using international benchmarks
- Market risk: Payor step edits, prior authorization, and formulary restrictions could reduce reimbursed patient access
- Reporting risk: Inaccurate rebate and chargeback estimates could reduce revenues, margins, and cash flows
AI summary of the HROW 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 7.01: Regulation FD Disclosure
- Corporate presentation furnished for investor conferences and meetings, signaling management’s current investor messaging
- Presentation content in Exhibit 99.1 may contain strategic, operational, or financial updates relevant to valuation
Item EX-99.1: Item EX-99.1
- Corporate presentation targets 2026 revenue of $350M-$365M, supported by Q3 revenue of $99.3M and $21.2M adjusted EBITDA
- Q3 branded revenue $83.5M, 79.3% branded gross margin, with VEVYE, IHEEZO and TRIESENCE generating $75.7M
Item 2.02: Results of Operations and Financial Condition
- Q3 2026 results for quarter ended September 30, 2026 announced November 9, 2026
- Stockholder letter includes updates on recent corporate developments
Item 7.01: Regulation FD Disclosure
- Exhibit 99.3 contains Harrow’s investor presentation for earnings calls, conferences and management meetings
- Presentation content may provide management’s latest business priorities and investor messaging
Item EX-99.2: Item EX-99.2
- Q3 revenue $99.3M, up 39% YoY, led by branded products at $83.5M, up 62%
- GAAP net income $9.8M included a $5.0M litigation settlement gain, limiting earnings quality
Item EX-99.1: Item EX-99.1
- Q3 revenue $99.3M, up 39% YoY, led by branded revenue of $83.5M, approximately 84% of total revenue
- GAAP net income $9.8M benefited from a $5.0M litigation settlement gain, while nine-month net loss reached $35.1M
Item EX-99.3: Item EX-99.3
- Q3 revenue $99.3M, up 41% QoQ and 39% YoY, with adjusted EBITDA $21.2M, up 62% YoY
- FY2026 revenue outlook reaffirmed at $350M-$365M, requiring implied Q4 revenue of $135.8M-$150.8M
Item 1.01: Entry into a Material Definitive Agreement
- TYRVAYA acquisition scope narrowed: Viatris retains Japanese commercialization rights
- Closing cash consideration fixed at $30.0 million, eliminating net working capital adjustment uncertainty
Item 2.01: Completion of Acquisition or Disposition of Assets
- TYRVAYA rights acquired globally excluding Japan, including regulatory approvals, intellectual property, technology, inventory and contracts
- $30.0 million upfront cash payment, funded from cash on hand, reducing liquidity
Item EX-99.1: Item EX-99.1
- TYRVAYA acquisition closed for $30 million cash, with up to $70 million sales-based milestones, potential consideration $100 million
- Worldwide rights acquired except Japan, with Viatris retaining Japan commercialization and paying Harrow royalties
Item 7.01: Regulation FD Disclosure
- Harrow completed its acquisition of the Acquired Assets on October 5, 2026
- Exhibit 99.1 contains the acquisition announcement and transaction details for investor review
AI summaries of HROW 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for HROW
Don't miss the next HROW filing
- Alerts as it files. A push when HROW files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut HROW, by share count.
- Ask anything. An AI agent that reads every HROW filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Shojaei Amir | M | Aug 14, 2026 | 11,250 | $35.96 |
| Shojaei Amir | M | Aug 14, 2026 | 11,250 | $35.96 |
| Shojaei Amir | Sell | Aug 14, 2026 | 11,250 | $40.00 |
| Graves Adrienne L | A | Jun 18, 2026 | 5,248 | - |
| SILVERNAIL LAUREN P | A | Jun 18, 2026 | 5,248 | - |
| Sternberg Perry J. | A | Jun 18, 2026 | 5,248 | - |
| Graves Adrienne L | Buy | May 18, 2026 | 1,000 | $31.07 |
| SILVERNAIL LAUREN P | Buy | May 18, 2026 | 1,000 | $31.00 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $199.6M | $272.3M |
| Gross Profit | - | $150.4M | $204.4M |
| Operating Income | - | $8.8M | $30.5M |
| Net Income | - | -$17.5M | -$5.1M |
| Gross Margin | - | 75.3% | 75.1% |
| Op. Margin | - | 4.4% | 11.2% |
| Net Margin | - | -8.8% | -1.9% |
| Balance Sheet | |||
| Total Assets | $312.2M | $389.0M | $399.5M |
| Equity | $70.8M | $69.7M | $52.4M |
| ROE | - | -25.1% | -9.8% |
| Per Share | |||
| EPS | - | $-0.49 | $-0.14 |
| Cash Flow | |||
| Operating CF | - | -$22.2M | $43.9M |
| CapEx | - | $1.6M | $887K |
Source: XBRL data in HARROW, INC. (HROW)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate HROW share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 27 | $265.4M |
| Q2 2026 | 27 | $323.9M |
| Q1 2026 | 26 | $252.2M |
| Q4 2025 | 25 | $383.7M |
| Q3 2025 | 25 | $365.8M |
| Q2 2025 | 24 | $247.9M |
| Q1 2025 | 20 | $136.9M |
| Q4 2024 | 16 | $164.0M |
- BlackRock+216.3K (+8%)
- Citadel Advisors LLC+161.0K (+45%)
- State Street Corp+85.0K (+9%)
- Goldman Sachs Group+76.5K (+49%)
- Dimensional Fund Advisors+54.8K (+8%)
- Vanguard Capital Management LLC−22.5K (-2%)
- Wells Fargo & Co−20.3K (-64%)
- Renaissance Technologies LLC−16.1K (-36%)
- Ameriprise Financial−10.2K (-49%)
- Northern Trust−8.0K (-2%)
- Franklin Resources+410.0K
- D.E. Shaw & Co+103.7K
- Soros Fund Management+20.2K
- AQR Capital Management+8.7K
- Millennium Management−84.2K
- Two Sigma Investments−22.5K
- FMR LLC (Fidelity)−5.2K
- U.S. Bancorp−268
Source: 13F-HR filings on SEC EDGAR (aggregated from 190 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
HROW filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 8-K | Nov 16, 2026 | - | Analysis | - |
| 8-K | Nov 9, 2026 | - | Analysis | - |
| 10-Q | Nov 9, 2026 | Sep 30, 2026 | Analysis | |
| 8-K | Oct 5, 2026 | - | Analysis | - |
| 8-K | Sep 4, 2026 | - | Analysis | - |
| 4 | Aug 17, 2026 | - | - | - |
| 10-Q | Aug 10, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 10, 2026 | - | Analysis | - |
| 8-K | Aug 6, 2026 | - | Analysis | - |
| 4 | Jun 22, 2026 | - | - | - |
| 4 | Jun 22, 2026 | - | - | - |
| 4 | Jun 22, 2026 | - | - | - |
| 8-K | Jun 22, 2026 | - | Analysis | - |
| 8-K | Jun 3, 2026 | - | Analysis | |
| 4 | May 19, 2026 | - | - | |
| 4 | May 19, 2026 | - | - | |
| 4 | May 18, 2026 | - | - | |
| 8-K | May 11, 2026 | - | Analysis | |
| 10-Q | May 11, 2026 | Mar 31, 2026 | Analysis | |
| 8-K | Mar 27, 2026 | - | - | - |
| 8-K | Mar 24, 2026 | - | - | - |
| 8-K | Mar 24, 2026 | - | - | - |
| SC 13G | Mar 11, 2026 | - | - | |
| 8-K | Mar 10, 2026 | - | Analysis | - |
| 4 | Mar 5, 2026 | - | - | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
HROW SEC filings: frequently asked questions
Which institutions hold HROW stock?
As of September 30, 2026, the largest HARROW, INC. (HROW) holders among the 13F filers tracked by SignalX were BlackRock ($91.1 million), Vanguard Capital Management LLC ($43.0 million), State Street Corp ($31.6 million), Dimensional Fund Advisors ($22.2 million), Citadel Advisors LLC ($16.0 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was HROW's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), HARROW, INC. (HROW) reported revenue of $272.3 million (up 36.4% from FY2024) and a net loss of $5.1 million. Diluted EPS was -$0.14. The figures come from the XBRL data in the 10-K.
What are the main risks in HROW's latest 10-K?
In the 10-K filed March 2, 2026, HARROW, INC. (HROW) flagged: Legal risk: Ocular Science lawsuit with $11.25M judgment after punitive damages reduction and pending appeal filed October 9, 2025. Macroeconomic risk: Sole U.S. revenue and asset concentration with 90% accounts receivable from three customers as of December 31, 2025. (AI summary of the Risk Factors section.)
What did HROW report in its latest 8-K?
HARROW, INC. (HROW) filed an 8-K on November 16, 2026 reporting Item 7.01 (Regulation FD Disclosure). Corporate presentation furnished for investor conferences and meetings, signaling management’s current investor messaging.
What are the latest HROW SEC filings?
HARROW, INC. (HROW) filed its latest 10-K annual report on March 2, 2026, a 10-Q quarterly report on November 9, 2026, an 8-K current report on November 16, 2026 and a Form 4 insider filing on August 17, 2026.
What is HROW's SEC CIK number?
HARROW, INC. (HROW)'s SEC Central Index Key (CIK) is 1360214. EDGAR lists every HROW filing under that number.
Ask anything about HROW
The research agent reads HROW's filings, financials, insider trades and 13F holders, then answers with sources.